Table 2.
Clinical characteristics of 1013 glioma patients in the CGGA dataset according to ITGB2 expression levels
| Variable | N | Overall, N = 10131 |
High, N = 5061 |
Low, N = 5071 |
p value2 |
|---|---|---|---|---|---|
| Age | 1012 | 43 (12) | 45 (13) | 42 (11) | < 0.001 |
| Gender | 1013 | 0.2 | |||
| Female | 421 (42%) | 200 (40%) | 221 (44%) | ||
| Male | 592 (58%) | 306 (60%) | 286 (56%) | ||
| Survival | 979 | 39 (35) | 31 (29) | 47 (39) | < 0.001 |
| Status | 985 | < 0.001 | |||
| Alive | 388 (39%) | 144 (29%) | 244 (49%) | ||
| Dead | 597 (61%) | 347 (71%) | 250 (51%) | ||
| Grade | 1013 | < 0.001 | |||
| II | 291 (29%) | 104 (21%) | 187 (37%) | ||
| III | 334 (33%) | 157 (31%) | 177 (35%) | ||
| IV | 388 (38%) | 245 (48%) | 143 (28%) | ||
| Histology | 1013 | ||||
| Anaplastic astrocytoma | 214 (21%) | 119 (24%) | 95 (19%) | ||
| Anaplastic oligoastrocytoma | 21 (2.1%) | 8 (1.6%) | 13 (2.6%) | ||
| Anaplastic oligodendroglioma | 94 (9.3%) | 29 (5.7%) | 65 (13%) | ||
| Astrocytoma | 175 (17%) | 85 (17%) | 90 (18%) | ||
| GBM | 388 (38%) | 245 (48%) | 143 (28%) | ||
| Oligoastrocytoma | 9 (0.9%) | 1 (0.2%) | 8 (1.6%) | ||
| Oligodendroglioma | 112 (11%) | 19 (3.8%) | 93 (18%) | ||
| Subtype | 432 | < 0.001 | |||
| Classical | 160 (37%) | 95 (35%) | 65 (41%) | ||
| Mesenchymal | 115 (27%) | 98 (36%) | 17 (11%) | ||
| Proneural | 157 (36%) | 80 (29%) | 77 (48%) | ||
| IDH_status | 961 | < 0.001 | |||
| Mutant | 529 (55%) | 209 (43%) | 320 (67%) | ||
| Wildtype | 432 (45%) | 273 (57%) | 159 (33%) | ||
| Recurrence | 1013 | 0.057 | |||
| Primary | 651 (64%) | 307 (61%) | 344 (68%) | ||
| Recurrent | 332 (33%) | 182 (36%) | 150 (30%) | ||
| Secondary | 30 (3.0%) | 17 (3.4%) | 13 (2.6%) | ||
| Radio_status | 927 | 0.050 | |||
| No | 162 (17%) | 68 (15%) | 94 (20%) | ||
| Yes | 765 (83%) | 386 (85%) | 379 (80%) | ||
| Chemo_status | 906 | 0.040 | |||
| No | 273 (30%) | 122 (27%) | 151 (33%) | ||
| Yes | 633 (70%) | 330 (73%) | 303 (67%) |
1Mean (SD); n (%)
2Welch two-sample t test; Pearson’s Chi-squared test